BioCentury | Nov 10, 2020
Finance

Nov. 9 Quick Takes: Biogen sheds $14B in value; plus Ambrx’s 200M round, Decibel’s series D and more

...also included contributions from Panacea Venture, Kunlun Capital and SCVC.Memo raises $16M for COVID-19 programSwiss biotech Memo Therapeutics AG...
...intraday on Monday, still far below Thursday’s close at $15.90.TARGETSOTOF – Otoferlin BC Staff Decibel Therapeutics Biogen Ambrx Homology Pfizer Inmagene Biopharmaceuticals Co. Ltd. Memo Therapeutics Assembly...
BioCentury | Jul 27, 2015
Financial News

Memo Therapeutics completes venture financing

Memo Therapeutics AG , Basel, Switzerland Business: Antibodies, Supply/Service Date completed: 2015-07-22 Type: Venture financing Raised: CHF2.3 million ($2.4 million) Investors: Redalpine Venture Partners; Zuercher Kantonalbank; EVA Basel WIR Staff...
Items per page:
1 - 2 of 2
BioCentury | Nov 10, 2020
Finance

Nov. 9 Quick Takes: Biogen sheds $14B in value; plus Ambrx’s 200M round, Decibel’s series D and more

...also included contributions from Panacea Venture, Kunlun Capital and SCVC.Memo raises $16M for COVID-19 programSwiss biotech Memo Therapeutics AG...
...intraday on Monday, still far below Thursday’s close at $15.90.TARGETSOTOF – Otoferlin BC Staff Decibel Therapeutics Biogen Ambrx Homology Pfizer Inmagene Biopharmaceuticals Co. Ltd. Memo Therapeutics Assembly...
BioCentury | Jul 27, 2015
Financial News

Memo Therapeutics completes venture financing

Memo Therapeutics AG , Basel, Switzerland Business: Antibodies, Supply/Service Date completed: 2015-07-22 Type: Venture financing Raised: CHF2.3 million ($2.4 million) Investors: Redalpine Venture Partners; Zuercher Kantonalbank; EVA Basel WIR Staff...
Items per page:
1 - 2 of 2